Contribute Try STAT+ Today

A pivot towards reselling Chinese-made coronavirus antibody tests in the U.S. has transformed tiny Aytu Bioscience (AYTU) into an overnight Covid-19 success story, with a soaring share price to match.

But the retail-investor frenzy behind the company’s unprecedented surge since early March disregards numerous risks and red flags. Any or all of them could send its stock price crashing lower. The Covid-19 pandemic has been devastating, but it will end — and so will the stock market bubble in micro-cap companies like Aytu.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.